BMS sells Asian OTC products to Taisho
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb is to sell a package of over-the-counter drugs sold in Asia Pacific to Taisho Pharmaceutical of Japan. Taisho will pay $310 million for assets relating primarily to products sold in Indonesia, Thailand and The Philippines, and for BMS's 97.97% stake in its Jakarta-based subsidiary PT Bristol-Myers Squibb Indonesia (BMSI).